Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | MMP12 | P39900 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7475648 | 0.88 | HPGD (0.58) | HPGDGAASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL3504947 | 0.88 | HPGD (0.58) | HPGDGAASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL9372814 | 0.88 | HPGD (0.58) | HPGDGAASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL21883044 | 0.87 | ALDH1A1 (0.62) | HPGDSMN1; SMN2MAPTALDH1A1FKBP1A | |
| SCHEMBL6639156 | 0.87 | ACE (0.59) | HPGDALDH1A1FKBP1ALTA4H | |
| SCHEMBL10509005 | 0.87 | ACE (0.59) | HPGDALDH1A1FKBP1ALTA4H | |
| SCHEMBL30600066 | 0.81 | DPP4 (0.45) | HPGDSMN1; SMN2ALDH1A1LMNARAB9A | |
| SCHEMBL8828176 | 0.81 | KDM4E (0.55) | GAAALDH1A1LMNAHSD17B10FKBP1A | |
| SCHEMBL18767537 | 0.80 | ALDH1A1 (0.57) | HPGDGAASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL23747793 | 0.78 | PKM (0.58) | SMN1; SMN2MAPTALDH1A1RAB9ADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10369120-B2 | T type calcium channel inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2019-08-06 | — | — | US | disclosed |
| US-20160136115-A1 | T TYPE CALCIUM CHANNEL INHIBITORS | UNIVERSITY OF VIRGINIA | 2016-05-19 | — | — | US | disclosed |
| US-9212127-B2 | T type calcium channel inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-12-15 | — | — | US | disclosed |
| US-20120264804-A1 | T TYPE CALCIUM CHANNEL BLOCKERS AND THE TREATMENT OF DISEASES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-10-18 | — | — | US | disclosed |
| US-20090234019-A1 | T Type Calcium Channel Inhibitors | UNIVERSITY OF VIRGINIA | 2009-09-17 | — | — | US | disclosed |
| US-20080194669-A1 | T Type Calcium Channel Blockers and the Treatment of Diseases | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-08-14 | — | — | US | disclosed |
| US-6946475-B1 | Phenyl substituted pyrrole and pyridine compounds as nontoxic antiproliferative agents. | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2005-09-20 | — | — | US | disclosed |
| EP-1165508-B1 | ANTICANCER CALCIUM CHANNEL BLOCKERS | THE UNIVERSITY OF VIRGINIA PAT (US) | 2004-06-23 | — | — | EP | disclosed |
| EP-1165508-A1 | ANTICANCER CALCIUM CHANNEL BLOCKERS | Gray, Lloyd S. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059882-A9 | ANTICANCER CALCIUM CHANNEL BLOCKERS | GRAY LLOYD S (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2000059882-A1 | ANTICANCER CALCIUM CHANNEL BLOCKERS | GRAY LLOYD S (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264804-A1 | T TYPE CALCIUM CHANNEL BLOCKERS AND THE TREATMENT OF DISEASES | CACNA1H, CACNA1G, CACNA1I | HPGD 2015/4885GAA 811/4885SMN1; SMN2 567/4885 |
| US-20080194669-A1 | T Type Calcium Channel Blockers and the Treatment of Diseases | CACNA1I, CACNA1H, CACNA1G | HPGD 1256/4885GAA 1943/4885SMN1; SMN2 1896/4885 |
| US-20090234019-A1 | T Type Calcium Channel Inhibitors | CACNA1H, CACNA1I, CACNA1G | HPGD 2317/4885GAA 3183/4885SMN1; SMN2 1194/4885 |
| US-10369120-B2 | T type calcium channel inhibitors | CACNA1H, CACNA1I, CACNA1G | HPGD 2317/4885GAA 3183/4885SMN1; SMN2 1194/4885 |
| US-20160136115-A1 | T TYPE CALCIUM CHANNEL INHIBITORS | CACNA1H, CACNA1I, CACNA1G | HPGD 2317/4885GAA 3183/4885SMN1; SMN2 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.